KAHR Medical Announces FDA Clearance of IND Application for DSP107, Anti-CD47 Candidate for the Treatment of Solid Tumours

KAHR Medical Announces FDA Clearance of IND Application for DSP107, Anti-CD47 Candidate for the Treatment of Solid Tumours


Phase I/II study in patients with solid tumours expected to commence in Q3 2020 at leading sites in the United States
JERUSALEM, Aug. 12, 2020 -- KAHR Medical, a cancer immunotherapy company developing novel bi-functional fusion proteins, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug (IND) application for the Company's lead product, DSP107, a second-generation CD47x41BB targeting compound that simultaneously target cancer cells, weaken their innate defences and activate an effective, local response of both innate and adaptive immunity.

Under this IND, the Company intends to initiate a phase I/II clinical trial to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of DSP107 as a monotherapy and in combination with Roche's PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq®) in patients with advanced solid tumours. The study will be conducted at multiple centres in the United States and site activation activities are currently underway. 

"Receiving clearance from the FDA to advance our lead immuno-oncology program to the clinic marks a significant milestone for KAHR as we transform into a clinical-stage company," said Yaron Pereg, PhD, CEO, KAHR Medical. "DSP107, with its unique dual mechanism of action and its excellent safety profile with no haematological toxicities has the potential to become a best-in-class CD47 therapy.  We are proud of our significant progress in recent years and look forward to initiating the phase I/II study in the upcoming weeks for the benefit of patients suffering from challenging to treat cancers," added Dr Pereg. 

The planned phase I/II study will evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of DSP107 in advanced solid tumours. The preliminary efficacy of both DSP107 monotherapy and combination therapy with atezolizumab will also be evaluated in patients with advanced non-small-cell lung carcinoma (NSCLC) who progressed after treatment with PD-1/PD-L1 inhibitors. The study will be conducted under a clinical collaboration with Roche.


About DSP107
DSP107 targets CD47-overexpressing tumours, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal to tumour antigen-specific, activated T-cells. CD47 is overexpressed on many cancer cells and binds SIRPα on immune phagocytic cells to produce a 'don't eat me' signal. DSP107 binds CD47 on cancer cells, blocking interaction with SIRPα and thus, blocking the "don't eat me signal". Simultaneously, DSP107 binds 41BB on T-cells, stimulating their activation. These activities lead to targeted immune activation through both macrophage and T-cell mediated tumour destruction. 


About KAHR Medical
KAHR Medical develops the next generation of immuno-oncology drug candidates for the treatment of multiple types of cancer. Its proprietary technology enables the construction of targeted biological drugs generated by the fusion of the active extracellular domains of a TNF-SF ligand and a type-I membrane protein. These Dual Signaling Proteins (DSPs) have two functional ends, which can simultaneously block and/or activate multiple reinforcing biological signals resulting in a synergistic outcome. The unique DSP composition ensures target activation and increased potency by assembling a high multimer protein structure which is essential for activation of the TNF receptor family. Investors in the Company include Flerie Invest AB, Oriella Limited a Consensus Business Group Limited subsidiary, HBL, Pavilion Capital, Mirae Asset, Korean Investment Partners and DSC Investments. For more information, please visit https://kahr-medical.com/.


Company contact:
Tsipi Haitovsky
Global Media Liaison
KAHR Medical
+972-52-5989-892
Tsipihai5@gmail.com
SOURCE KAHR Medical